http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2243780-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2004-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56b5e0a570ceebacbfac8e91e29da385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4df299643d8fa64e3e9fa33443f326ff |
| publicationDate | 2005-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2243780-C1 |
| titleOfInvention | Method for treating postoperational abscesses of abdominal cavity |
| abstract | FIELD: medicine, purulent surgery. n SUBSTANCE: one should perform generally accepted medicinal therapy, moreover, one should prescribe additional chemotrypsin during the first 1-2 d after operation to be locally injected twice-thrice during day-time period at concentration of 0.5-1.0 mg/ml of 10%-sodium chloride solution at exposure of 1.5-2 h at the quantity of one fourth up to one third against the purulent volume removed out of abscess cavity, then therapy course should be supplemented with bacteriophage which should be locally injected twice during day-time period at daily dosage being 200 ml, not more at exposure of 1.5-2 h at the quantity of one tenth up to one fifth against purulent volume removed out of abscess cavity. As for bacteriophage type, it should be matched in accordance to the results of bacteriological survey of abscess cavitary content. Therapy course lasts for 6-9 d. n EFFECT: higher efficiency of therapy. n 2 ex |
| priorityDate | 2004-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.